UNASSIGNED: Relapse after transplantation is a major cause of treatment failure in paediatric @entity981 ( @entity981 ). Here, we report the findings of a prospective national study designed to investigate the feasibility of immune intervention in @entity1 in first or subsequent remission following myeloablative conditioning. This study included 133 @entity1 who received a transplant for @entity981 between 2005 and 2008. @entity41 ( @entity41 ) based on T cell receptor/immunoglobulin gene rearrangements was measured on days -30, 30, 90 and 150 post-transplantation. @entity205 treatment was rapidly discontinued and donor lymphocyte infusions (DLI) were programmed for @entity1 with a pre- or post-transplant @entity41 status >= 10(-3) . Only nine @entity1 received DLI. Pre- and post-transplant @entity41 status, and the duration of @entity205 were independently associated with 5-year @entity1349 ( @entity1349 ), which was 62  07% for the whole cohort. @entity1349 was substantially higher in @entity1 cleared of @entity41 than in those with persistent @entity41 (52  3% vs. 14  3%, respectively). Only pre-transplant @entity41 status (Hazard Ratio 2  57, P  =  0  04) and duration of @entity205 treatment (P  <  0  001) were independently associated with relapse. The kinetics of chimerism were not useful for predicting relapse, whereas @entity41 monitoring up to 90  d post-transplantation was a valuable prognostic tool to guide therapeutic intervention.

Follow-up of post-transplant minimal residual disease and chimerism in XXXX : 90  d to react.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukaemia', 'ALL'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'Minimal Residual Disease'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['Ciclosporin', 'ciclosporin'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity981 :: (MESH:D054198,Disease) :: ['childhood lymphoblastic leukaemia']
